The invention relates to plasma or liver lipid species selected from the triacylglycerol (TAG) and cardiolipin (CL) lipid classes measured by LC-MS/MS and use thereof as diagnostic and prognostic biomarkers of fatty liver, as well as to monitor the efficacy of preventive and therapeutic measures to lower liver fat content.
Kristina Schoonjans, Alessia Perino, Hadrien Charles Edouard Demagny
Kristina Schoonjans, Petar Petrov